Moneycontrol PRO
Upcoming Event:Attend Algo Convention Live, 2 Days & 12+ Speakers at best offer Rs.999/-, exclusive for Moneycontrol Pro subscribers. Register now!
you are here: HomeNewsBusiness

Cadila Healthcare gets EIR from USFDA for Baddi facility

"The company's formulations manufacturing facility located at Baddi, India, has received an EIR. The United States Food and Drug Administration (USFDA) had conducted an inspection at the facility from July 15 to 19, 2019," Cadila Healthcare said in a filing to BSE.

October 31, 2019 / 01:59 PM IST

Drug firm Cadila Healthcare on Thursday said its Baddi facility in Himachal Pradesh has received establishment inspection report (EIR) from the US health regulator.

"The company's formulations manufacturing facility located at Baddi, India, has received an EIR. The United States Food and Drug Administration (USFDA) had conducted an inspection at the facility from July 15 to 19, 2019," Cadila Healthcare said in a filing to BSE.

The EIR report stated that the classification of the facility is 'No Action Indicated (NAI)', it added.

Shares of Cadila Healthcare were trading at Rs 252.35 per scrip on BSE, up 0.96 percent from its previous close.



Download your money calendar for 2022-23 here and keep your dates with your moneybox, investments, taxes

PTI
first published: Oct 31, 2019 01:56 pm
Sections
ISO 27001 - BSI Assurance Mark